ALK-Abelló A/S (AKBLF)

Market Cap	9.02B +66.5%
Revenue (ttm)	1.01B +14.9%
Net Income	197.46M +36.6%
EPS	0.89 +38.3%
Shares Out	n/a
PE Ratio	45.67
Forward PE	38.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	38.89
Previous Close	35.55
Day's Range	38.89 - 38.89
52-Week Range	26.99 - 38.89
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About ALK-Abelló

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,759
• Stock Exchange: OTCMKTS
• Ticker Symbol: AKBLF

Financial Performance

In 2025, ALK-Abelló's revenue was 6.31 billion, an increase of 14.00% compared to the previous year's 5.54 billion. Earnings were 1.20 billion, an increase of 46.87%.

Financial numbers in DKK